IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies

Featuring an interview with Dr Patrick Y Wen, including the following topics:

• Glioma classification (0:00)
• Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
• Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
• Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
• Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
• Current and emergent strategies for the management of glioblastoma (31:27)
• Optimizing patient care and quality of life (46:24)

CME information and select publications